A complete LOI framework built for RCM and medical billing acquisitions — covering purchase price structures, client retention earnouts, HIPAA representations, and SBA financing terms specific to the $1M–$5M revenue segment.
A letter of intent (LOI) in a medical billing company acquisition is more than a price placeholder — it is the document that frames every major risk and economic term before attorneys begin drafting the definitive agreement. Medical billing businesses present unique LOI considerations that generic templates miss entirely. Revenue is service-based with no hard assets, meaning the entire purchase price is justified by recurring contract cash flows from physician practices, specialty groups, or hospital outpatient departments. Client concentration risk — where one or two large practices may represent 30–40% of collections-based revenue — must be addressed directly in the LOI through earnout mechanics or escrow holdbacks tied to post-close client retention. HIPAA compliance exposure, payer audit history, and the transferability of business associate agreements (BAAs) all need preliminary acknowledgment before the buyer commits capital. SBA 7(a) financing is commonly used for acquisitions in this segment, and lenders will require the LOI to clearly define the enterprise value, any seller note component, and working capital expectations. A well-drafted LOI for an RCM business acquisition typically runs 6–10 pages and covers purchase price, deal structure, earnout triggers, exclusivity, confidentiality, due diligence scope, and closing conditions — each calibrated to the specific operational and regulatory profile of outsourced medical billing.
Find Medical Billing Company Businesses to AcquireParties and Transaction Overview
Identifies the buyer entity, seller entity, and the specific business being acquired — including whether the deal is structured as an asset purchase or stock purchase. Most medical billing acquisitions close as asset purchases to allow the buyer to exclude unknown compliance liabilities, particularly undisclosed payer audit exposure or historical billing irregularities.
Example Language
This Letter of Intent is entered into as of [Date] by and between [Buyer Entity Name], a [State] [LLC/Corporation] ('Buyer'), and [Seller Entity Name], a [State] [LLC/Corporation] ('Seller'), with respect to Buyer's proposed acquisition of substantially all of the assets of [Medical Billing Company Name] ('Company'), a medical billing and revenue cycle management services business generating approximately $[X] in annual revenue and $[X] in EBITDA for the trailing twelve months ended [Date]. The proposed transaction shall be structured as an asset purchase, with Buyer assuming only those liabilities expressly identified in the definitive Asset Purchase Agreement.
💡 Sellers frequently prefer a stock sale to receive capital gains treatment and avoid asset transfer logistics, including client contract reassignments. Buyers — particularly those using SBA 7(a) financing — nearly always push for an asset purchase to obtain a stepped-up tax basis and limit exposure to pre-close HIPAA violations, undisclosed payer audits, or improper billing claims that could trigger CMS clawback demands. If a seller insists on a stock sale, buyers should demand a materially higher indemnification escrow, often 15–20% of purchase price held for 24–36 months, to cover regulatory tail risk.
Purchase Price and Valuation Basis
States the proposed enterprise value, the valuation methodology used to arrive at that figure, and any purchase price adjustments tied to working capital, client revenue run rate, or EBITDA confirmation at close. Medical billing companies in the $1M–$5M revenue range typically trade at 3.5x–6.0x trailing twelve-month EBITDA, with the multiple driven primarily by client diversification, contract quality, net collection rate performance, and technology infrastructure.
Example Language
Buyer proposes to acquire the Company for a total enterprise value of $[X] ('Purchase Price'), representing approximately [X.Xx] times the Company's trailing twelve-month EBITDA of $[X] as reflected in the financial statements provided to Buyer. The Purchase Price is subject to adjustment at closing based on a normalized working capital target of $[X], representing accounts receivable net of deferred revenue and accrued liabilities. In the event the Company's annualized recurring revenue from active client contracts falls below $[X] as of the close date, the Purchase Price shall be reduced on a dollar-for-dollar basis for each dollar of revenue shortfall below such threshold.
💡 The valuation multiple for a medical billing company is highly sensitive to client concentration. A business where the top two clients represent more than 35% of total billing revenue should be priced at the lower end of the 3.5x–4.5x range, with a larger portion of consideration deferred through earnout. Sellers with documented long-term contracts, 95%+ net collection rates, and a diversified book spanning five or more specialties can credibly argue for 5x–6x EBITDA. Buyers should confirm whether the seller's EBITDA calculation adds back owner compensation above market rate — a common inflation tactic — and should restate EBITDA using a market-rate management salary of $120,000–$180,000 before applying the multiple.
Deal Structure and Financing
Outlines how the purchase price will be funded, including the SBA 7(a) loan amount, seller note terms, earnout component, and any equity rollover. The structure should be explicit enough for both the seller to evaluate net proceeds and for the SBA lender to confirm the loan is structured within program guidelines.
Example Language
The Purchase Price of $[X] shall be funded as follows: (i) $[X] from proceeds of an SBA 7(a) loan obtained by Buyer from [Lender Name] ('SBA Loan'), representing approximately [X]% of the total Purchase Price; (ii) a seller promissory note in the principal amount of $[X] bearing interest at [X]% per annum, with monthly principal and interest payments over a [24/36/60]-month term commencing 90 days following the close date ('Seller Note'), representing approximately [X]% of the total Purchase Price; and (iii) an earnout of up to $[X] payable over 24 months following close, contingent upon the retention of client contracts representing no less than [X]% of the Company's trailing twelve-month billing revenue as further described in Section [X] hereof.
💡 SBA 7(a) loans for medical billing acquisitions typically fund 80–90% of the purchase price, with lenders requiring the seller note to be on full standby for the first 24 months. Sellers should understand that the standby requirement means they will not receive seller note payments during that window, which affects their net present value calculation. Earnout components of 15–25% of purchase price are increasingly common in RCM acquisitions to bridge the valuation gap created by client concentration risk — buyers want proof that clients will stay before paying full price. Sellers should push to define earnout measurement as total billing revenue processed, not collections received, to avoid penalization for payer-side delays outside their control.
Earnout Terms and Client Retention Mechanics
Defines the specific triggers, measurement periods, and payment mechanics for any earnout tied to client retention or revenue performance post-close. This is often the most heavily negotiated section in a medical billing LOI because the entire business value is dependent on whether existing physician practice clients remain with the new owner.
Example Language
Buyer shall pay Seller an earnout of up to $[X] over the 24-month period following the closing date ('Earnout Period'), calculated as follows: (i) if the Company retains client contracts representing 90% or more of trailing twelve-month recurring billing revenue as of the close date through Month 12, Buyer shall pay Seller $[X] within 30 days following the end of Month 12; (ii) if the Company retains client contracts representing 90% or more of trailing twelve-month recurring billing revenue through Month 24, Buyer shall pay Seller an additional $[X] within 30 days following the end of Month 24; and (iii) earnout payments shall be prorated on a straight-line basis for client retention between 75% and 90% of baseline revenue, with no earnout payable if retention falls below 75%. For purposes of this section, client contract revenue shall be measured using the average monthly billing volume per client over the 90-day period preceding the close date, annualized.
💡 Sellers should insist on a seller-friendly definition of what constitutes 'client retention' — revenue lost due to a practice closing, merging, or going in-house should not count against the seller's earnout. Buyers should ensure the seller is contractually obligated to participate in client transition activities during the earnout period, including direct introductions to key contacts at the top 10 client accounts. Both parties should agree on an earnout dispute resolution mechanism — typically binding arbitration with a neutral accountant serving as arbitrator — to avoid litigation over measurement disputes. Sellers should also negotiate for accelerated earnout payment if the buyer triggers client departures through poor service delivery or unilateral fee increases.
Exclusivity and No-Shop Period
Grants the buyer an exclusive negotiating period during which the seller agrees not to solicit or entertain competing acquisition offers. This section is critical for buyers who need time to complete due diligence, obtain SBA lender approval, and engage legal counsel without the risk of being outbid while incurring deal costs.
Example Language
In consideration of Buyer's commitment to dedicate resources to due diligence and financing, Seller agrees that for a period of 60 days following full execution of this Letter of Intent ('Exclusivity Period'), Seller shall not, directly or indirectly, solicit, initiate, encourage, or respond to any inquiry, proposal, or offer from any third party relating to the sale, transfer, or other disposition of the Company or its assets. Seller shall promptly notify Buyer of any unsolicited acquisition inquiries received during the Exclusivity Period. The Exclusivity Period may be extended by mutual written agreement of the parties for up to two additional 15-day periods if due diligence or SBA financing approval remains in progress.
💡 Sixty days is the standard exclusivity window for SBA-financed lower middle market deals, though sellers with strong deal momentum or multiple interested buyers should push back to 45 days. Sellers should ensure the LOI includes a provision that exclusivity terminates automatically if the buyer fails to deliver a comprehensive due diligence request list within 10 business days of LOI execution — this prevents a buyer from holding the seller in exclusivity without actively pursuing the deal. Buyers should include a mechanism to extend exclusivity if the SBA lender requires additional information, as lender processing times for healthcare services businesses can run 45–75 days.
Due Diligence Scope and Process
Outlines the categories of information the buyer will review during the due diligence period, the timeline for document delivery, and the process for managing sensitive HIPAA-protected information. Medical billing acquisitions require specialized due diligence that goes well beyond financial statements, including compliance audits, client contract review, and technology infrastructure assessment.
Example Language
Buyer's due diligence review shall include, without limitation: (i) three years of CPA-prepared or reviewed financial statements with revenue broken out by client and specialty; (ii) all client contracts, including fee schedules, term lengths, renewal provisions, and termination for convenience clauses; (iii) HIPAA compliance documentation including all executed Business Associate Agreements, security risk assessments conducted within the past 24 months, breach notification history, and any correspondence with OCR or state privacy regulators; (iv) collection rate reports and denial management performance metrics by client and payer for the trailing 24 months; (v) all software licenses, EHR integration agreements, and technology vendor contracts; (vi) employee records including coder certifications (CPC, CCS), tenure, compensation, and any non-solicitation agreements; and (vii) documentation of any payer audits, prepayment reviews, or recoupment demands received in the past 36 months. Seller shall provide Buyer access to a secure virtual data room within 10 business days of LOI execution.
💡 HIPAA due diligence is non-negotiable and non-compressible — buyers who skip or rush this step expose themselves to seven-figure regulatory liability. Require the seller to produce executed BAAs with every current client and vendor before signing the definitive agreement; missing BAAs are a bright red compliance flag. Payer audit history is equally critical — request copies of all RAC, MAC, and commercial payer audit correspondence, even if resolved. Any history of improper billing, upcoding allegations, or false claims act inquiries must be disclosed and independently evaluated by healthcare regulatory counsel before the buyer commits to close.
Representations, Warranties, and Indemnification Framework
Establishes the preliminary framework for the seller's representations and warranties regarding the accuracy of financial information, compliance with HIPAA and payer rules, client contract status, and employee matters, along with the indemnification obligations that will survive closing to protect the buyer from pre-close liabilities.
Example Language
The definitive Asset Purchase Agreement shall include customary representations and warranties from Seller with respect to, among other matters: (i) the accuracy of all financial statements and absence of undisclosed liabilities; (ii) compliance with HIPAA, the HITECH Act, and applicable state privacy laws, including the execution and maintenance of Business Associate Agreements with all clients and covered vendors; (iii) the absence of any pending or threatened payer audits, CMS investigations, OIG inquiries, or False Claims Act proceedings; (iv) the enforceability of all client contracts and the absence of any material breach, termination notice, or non-renewal notice from any client representing more than 5% of trailing twelve-month revenue; and (v) the current and valid status of all employee coding certifications (CPC, CCS) and professional licenses. Seller shall indemnify Buyer for breaches of representations and warranties for a period of 36 months following close, with an indemnification cap of [X]% of the Purchase Price and a deductible of $[X,XXX].
💡 Healthcare-specific representations regarding HIPAA compliance and billing integrity carry longer indemnification survival periods than standard commercial reps — 36 months for general reps and 60 months or the applicable statute of limitations for fundamental reps and compliance-related reps is industry standard. Buyers should push for a specific carve-out from the indemnification cap for HIPAA violations, fraud and abuse matters, and False Claims Act exposure, treating these as uncapped or subject to a higher sublimit. Sellers should resist overly broad billing compliance representations and instead focus indemnification on known, disclosed items with a specific dollar reserve agreed at LOI stage.
Non-Compete and Transition Services
Establishes the preliminary terms of the seller's post-closing non-competition and non-solicitation obligations, as well as the scope and duration of any transition services agreement under which the seller will assist with client relationship handoffs, staff retention, and operational continuity during the post-close integration period.
Example Language
Seller and all principals of Seller shall execute a non-competition agreement at closing prohibiting direct or indirect engagement in outsourced medical billing or revenue cycle management services within [geographic area or nationwide] for a period of four years following the close date. Seller shall also execute a non-solicitation agreement prohibiting Seller from soliciting any client, employee, or vendor of the Company for a period of four years following the close date. Seller shall provide transition services to Buyer for a period of 12 months following close under a Transition Services Agreement to be negotiated in good faith, including client relationship introductions, staff mentorship, payer credentialing support, and assistance with any outstanding denial management or payer audit matters, at a monthly consulting fee of $[X,XXX].
💡 Non-compete enforceability varies significantly by state — California will not enforce them at all, while most other states require geographic and temporal reasonableness. For a medical billing company with national clients, a nationwide non-compete for three to four years is generally defensible. The transition services period is critical in this industry: clients have often worked exclusively with the selling owner for years, and an abrupt handoff without personal introduction from the seller creates churn risk that destroys earnout value for both parties. Sellers should negotiate the consulting fee to reflect their actual time commitment and should push for compensation tied to specific deliverables rather than open-ended availability.
Client Concentration Threshold and Earnout Trigger
Define the maximum acceptable client concentration at close and tie earnout mechanics directly to retention of clients above the concentration threshold. For a medical billing company where one or two practices represent more than 25% of collections-based revenue, the LOI should specify that the earnout is weighted toward retention of those specific accounts, with a full earnout payout contingent on those anchor clients remaining active for 24 months post-close.
HIPAA and Compliance Indemnification Carve-Out
Negotiate a specific carve-out from the general indemnification cap for any liability arising from HIPAA violations, HITECH breaches, CMS billing fraud, or False Claims Act exposure that occurred prior to closing. These liabilities are binary in nature — a single OCR investigation or DOJ inquiry can produce seven-figure penalties — and should be treated as uncapped seller obligations regardless of what the general reps and warranties cap is set at.
Revenue Measurement Basis for Earnout
Specify whether earnout measurements are based on billing revenue processed (charges submitted) or collections received. Sellers should strongly prefer billing revenue as the measurement base since collection rates are partially dependent on payer behavior, denial rates, and practice-side factors outside the billing company's control after an ownership transition. Buyers prefer collections as the economic reality of the business, but a fair compromise is net collection rate against billed charges using a pre-agreed benchmark.
Seller Note Standby Period and Payment Commencement
SBA guidelines require seller notes to be on full standby for 24 months after close when used to complete an SBA 7(a)-financed acquisition. Sellers must understand this means no principal or interest payments during that window. Negotiate the seller note interest rate (typically prime plus 1–2%), amortization term, and any balloon payment structure upfront in the LOI so there are no surprises when the definitive agreement is drafted.
Technology and Software Transfer Terms
Address the transferability of all billing software licenses, EHR integration agreements, and practice management system contracts in the LOI. Many billing platform licenses are non-transferable or require vendor consent for assignment, which can delay closing by 30–60 days or require the buyer to re-license software at significantly higher rates. The LOI should allocate responsibility for obtaining necessary consents and specify which party bears re-licensing costs if vendor consent is required.
Key Employee Retention and Coder Certification Verification
Identify by role — if not by name — the critical coding staff, denial management specialists, and account managers whose retention is essential to post-close operations. The LOI should condition closing on the execution of employment agreements or retention bonuses for key personnel, and should require the seller to verify that all CPC and CCS certifications are current and in good standing as a closing condition. A single departing certified coder can materially impair collection rate performance.
Working Capital Peg and Accounts Receivable Treatment
Define how working capital will be measured and whether the purchase price includes or excludes the pre-close accounts receivable. In a percentage-of-collections billing business, AR timing creates significant complexity — the LOI should specify whether the seller retains the right to collect pre-close AR or whether it transfers to the buyer as part of working capital, and should set a normalized working capital peg based on 90-day trailing averages to avoid close-date manipulation.
Find Medical Billing Company Businesses to Acquire
Enough information to write a strong LOI on day one — free to join.
An LOI for a medical billing company acquisition is a preliminary agreement that outlines the key economic and structural terms of the proposed transaction before the parties invest in full legal documentation. The LOI typically covers purchase price, deal structure, earnout mechanics, exclusivity period, and a high-level due diligence framework. Most LOIs are intentionally non-binding on the core transaction terms — meaning neither party is legally obligated to close the deal — but certain provisions such as exclusivity, confidentiality, and governing law are typically written as binding obligations. In a medical billing acquisition, the LOI also serves as an early-stage risk allocation tool, flagging HIPAA compliance representations and client retention earnout mechanics that will require significant negotiation in the definitive agreement.
A medical billing company generating $600K in EBITDA with strong fundamentals would typically trade at 4x–6x EBITDA, implying an enterprise value range of $2.4M–$3.6M. Where the deal lands within that range depends primarily on client diversification — a business with 20 or more active physician practice clients and no single client exceeding 15% of revenue would command the upper end, while a business where two large group practices represent 50% of billing volume would be priced at 3.5x–4.5x with a meaningful portion deferred through earnout. Other value drivers include net collection rate performance above 95%, documented workflows, certified coding staff with low turnover, and clean HIPAA compliance history. If SBA 7(a) financing is used, lenders typically require the multiple to be supported by a formal business valuation, which buyers should commission before finalizing LOI price terms.
Client concentration risk should be addressed directly in the LOI through a combination of purchase price mechanics and earnout structure. If any single client represents more than 20–25% of trailing twelve-month billing revenue, the LOI should either apply a discounted valuation multiple to that revenue tranche or structure a portion of the purchase price as an earnout explicitly tied to that client's retention for 12–24 months post-close. The LOI should also specify that the seller must obtain written consent or acknowledgment from anchor clients prior to closing — or at minimum facilitate a direct ownership transition meeting — as a closing condition. Buyers who ignore concentration risk at the LOI stage frequently find themselves paying a full-price earnout on revenue that evaporates within six months of close when a large practice decides the new ownership relationship is not to their liking.
HIPAA compliance should be addressed at the LOI stage, at minimum by flagging it as a specific due diligence deliverable and a closing condition. The LOI should require the seller to deliver complete HIPAA documentation — including executed Business Associate Agreements with all clients and vendors, current security risk assessments, and a disclosure of any breach notification history — within the first 15 days of the due diligence period. The LOI should also establish that discovery of material HIPAA violations, missing BAAs, or undisclosed payer audit activity gives the buyer the right to terminate the LOI or renegotiate purchase price without penalty. Waiting until the definitive agreement to surface HIPAA issues wastes attorney time and deal momentum — a buyer who discovers that 30% of client BAAs are missing or expired at the 11th hour is in a much weaker negotiating position than one who flagged the issue in the LOI and built a cure obligation into the timeline.
A typical earnout in a medical billing acquisition represents 15–25% of the total purchase price and is structured over a 12–24 month post-close period, tied directly to client retention measured by billing revenue processed or collections received from existing client accounts. For example, on a $2.5M acquisition, a $500,000 earnout might be structured as $250,000 payable at Month 12 if 90% or more of pre-close client revenue is retained, and an additional $250,000 at Month 24 under the same threshold, with prorated payment for retention between 75% and 90% and no earnout below 75%. The most important earnout negotiation point is defining which client revenue losses count against the seller — most sellers will insist that revenue lost because a practice closes, sells, or goes in-house should be excluded from the retention calculation, while buyers will want to include all revenue shortfalls regardless of cause. Both parties should agree on a clear audit mechanism for earnout measurement and a dispute resolution process before signing the LOI.
Yes, medical billing companies are eligible for SBA 7(a) financing, and the majority of individual operator acquisitions in the $1M–$5M revenue range are funded primarily through SBA loans. An SBA 7(a) loan can fund 80–90% of the acquisition price, with the seller note covering the remaining 10–20%. This structure has important LOI implications: the seller note must be placed on full standby for 24 months per SBA guidelines, meaning the seller receives no payments on the note during that period. Buyers should disclose SBA financing intent in the LOI and include a financing contingency that makes closing conditional on SBA loan approval, specifying a deadline — typically 60–75 days — after which either party can terminate if financing is not secured. The LOI should also confirm that the transaction is structured as an asset purchase, as SBA lenders strongly prefer asset acquisitions for healthcare services businesses to limit collateral exposure to undisclosed regulatory liabilities.
From LOI execution to closing, a medical billing company acquisition in the $1M–$5M revenue range typically takes 90–150 days. The LOI itself should be drafted and executed within 1–2 weeks of initial price alignment. Due diligence runs 30–45 days for a well-prepared seller and can extend to 60–75 days if HIPAA documentation is incomplete, client contracts need to be located and organized, or payer audit history requires outside legal review. SBA lender processing adds another 30–60 days running in parallel with due diligence. Definitive agreement drafting and negotiation typically requires 3–4 weeks. Sellers who have completed an exit readiness checklist before going to market — with organized financials, executed BAAs, current client contracts, and documented workflows — consistently close in the 90–120 day range, while unprepared sellers routinely see deals fall apart or reprice during extended diligence periods.
More Medical Billing Company Guides
More LOI Templates
Get enough diligence data to write a confident LOI from day one.
Create your free accountNo credit card required
For Buyers
For Sellers